CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 334 enrolled
Drug / intervention
Tirbanibulin 2.5 mg ointmentdrug
Likely dose
Tirbanibulin 2.5 mg ointmentfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05741294
NCT05741294Phase 4Completed
CompareCT.gov

Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)

Almirall, S.A.·interventional·Posted Feb 23, 2023·Updated Feb 20, 2025

In Brief

A Phase 4 clinical trial evaluating Tirbanibulin 2.5 mg ointment for Actinic Keratosis. Completed, enrolled 334 participants across 37 sites in 2 countries.

Detailed Summary

The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5 consecutive days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesItaly, Spain
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedFeb 23, 2023
Enrollment StartJan 20, 2023
Primary CompletionJan 19, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.4 years ago

Interventions

Tirbanibulin 2.5 mg ointmentdrug

Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.